12
years since launch
More than
25
countries covered
More than
350
projects
More than
250
decision support models
Hari Group provides advisory services to firms looking to make decisions with limited information in the healthcare space. We have the skills and resources to conduct market, product and service evaluations globally including the emerging markets. We have extensive experience in conducting global opportunity assessments and have helped large, medium and small pharmaceutical, biotechnology and device companies around the world.
We have been in this space for over a decade and have conducted projects to support decisions around funding for early stage companies, on whether to progress an asset across phases of clinical trials, about drug licensing opportunities, on valuation of revenue streams for monetization and on pricing new products. We have also developed forecasts for hundreds of new products, including valuations for many. Hari Group directly conducts primary market research in the US, EU5, Japan, MENA and emerging markets globally. In addition, we also develop health economic evaluations – patient level microsimulation models and Markov models – to support pricing and reimbursement.
We have processes in place to provide results very rapidly to our clients with most projects taking less than 4 weeks from commissioning to delivery.
What we can do for you
Our core offerings are focused on businesses that develop, manufacture or market, pharmaceutical or biotechnology products and medical devices. We help you understand the potential of specific therapeutic areas, country markets, soon-to-be launched products and early stage molecules, including intellectual property. Our offerings are designed to maximize returns from your R&D, business development, licensing and marketing efforts.
Our services are built around primary market research, secondary research and data analysis with the outputs focused on strategy formulation, quantitative assessment of strategies, scenario analysis and development of strategic options for our clients. Our deliverables are developed to provide as much information as possible to the client along with the tools required to facilitate structured thinking.
We also run custom workshops and participate in on-site meetings as needed to provide support to our clients during projects and beyond.
We are unique in having the processes and resources in place to provide rapid turnarounds with global projects. In the past, we have conducted primary market research, run desk research and developed final deliverables, all in the space of 4 weeks for quite a few product evaluation projects.
Our services
Business strategy workshop
Portfolio strategy workshop
Disease area strategy workshop
Product strategy workshop
TPP testing and optimization
Product positioning assessment
Product opportunity assessment
Product sales forecasting with dynamic models
ROI assessment of clinical studies
ROI assessment of potential new indications
ROI assessment of potential new formulations
ROI assessment of planned marketing campaigns
Price elasticity assessment by country
Pricing and reimbursement assessment by country
Pricing and reimbursement strategy development
Development of health economic models
Business case development - inlicensing/ outlicensing
Business case development - early stage products
Business case development - royalty stream investment opportunities
Generic opportunity assessment
Our products
-
What’s the skinny behind the Repatha (Evolocumab) FOURIER trial results that were announced recently by Amgen?
£29.99 -
The impact of Brexit on the pharmaceutical landscape of the United Kingdom
£9.99 -
The Atopic Dermatitis market and the approval of Dupixent
£29.99 -
Multiple Sclerosis and the launch of Ocrevus
£29.99 -
A snapshot of the Indian pharma industry
£49.99 -
Outcomes-based contracting in the US pharmaceutical market
£19.99 -
Bladder cancer and immuno-oncology therapies
£29.99 -
Overview of the Prostate Cancer treatment landscape
£19.99 -
Overview of CAR-T therapies
£19.99 -
Overview of Kymriah (CAR-T therapy) by Novartis in ALL
£9.99 -
An overview of RNAi therapies
£19.99 -
Overview: Luxturna by Spark Therapeutics
£19.99
